409 related articles for article (PubMed ID: 20740617)
41. [Type I cryoglobulinemia with a fatal outcome].
Echeverría B; Vitiello M; Abuchar A; Kerdel FA
Actas Dermosifiliogr; 2011 Apr; 102(3):212-5. PubMed ID: 21376295
[TBL] [Abstract][Full Text] [Related]
42. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy.
Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040
[TBL] [Abstract][Full Text] [Related]
43. Non-infectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach.
Perez-Alamino R; Espinoza LR
Curr Rheumatol Rep; 2014 May; 16(5):420. PubMed ID: 24647999
[TBL] [Abstract][Full Text] [Related]
44. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
[TBL] [Abstract][Full Text] [Related]
45. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.
Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S
Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.
Gottenberg JE; Cinquetti G; Larroche C; Combe B; Hachulla E; Meyer O; Pertuiset E; Kaplanski G; Chiche L; Berthelot JM; Gombert B; Goupille P; Marcelli C; Feuillet S; Leone J; Sibilia J; Zarnitsky C; Carli P; Rist S; Gaudin P; Salliot C; Piperno M; Deplas A; Breban M; Lequerre T; Richette P; Ghiringhelli C; Hamidou M; Ravaud P; Mariette X;
Ann Rheum Dis; 2013 Jun; 72(6):1026-31. PubMed ID: 23264337
[TBL] [Abstract][Full Text] [Related]
47. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.
Matsukura S; Knowles SR; Walsh S; Shear NH
Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790
[TBL] [Abstract][Full Text] [Related]
48. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis.
Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM
Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358
[TBL] [Abstract][Full Text] [Related]
49. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.
Gottenberg JE; Ravaud P; Bardin T; Cacoub P; Cantagrel A; Combe B; Dougados M; Flipo RM; Godeau B; Guillevin L; Le Loët X; Hachulla E; Schaeverbeke T; Sibilia J; Baron G; Mariette X;
Arthritis Rheum; 2010 Sep; 62(9):2625-32. PubMed ID: 20506353
[TBL] [Abstract][Full Text] [Related]
50. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
Mani LY; Vogt B; Burnier M; Golshayan D
Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
[TBL] [Abstract][Full Text] [Related]
51. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
52. Refractory urticarial vasculitis as a complication of ulcerative colitis successfully treated with rituximab.
Swaminath A; Magro CM; Dwyer E
J Clin Rheumatol; 2011 Aug; 17(5):281-3. PubMed ID: 21778903
[TBL] [Abstract][Full Text] [Related]
53. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey.
Brah S; Chiche L; Fanciullino R; Bornet C; Mancini J; Schleinitz N; Jean R; Kaplanski G; Harlé JR; Durand JM
Ann Hematol; 2012 Feb; 91(2):279-85. PubMed ID: 21710166
[TBL] [Abstract][Full Text] [Related]
55. [Monoclonal antibodies to B-lymphocytes (rituximab) in the treatment of HCV-associated severe cryoglobulinemic glomerulonephritis].
Milovanova SIu; Lopatkina TN; Kozlovskaia LV; Krasnova TN
Ter Arkh; 2007; 79(6):69-72. PubMed ID: 17684972
[No Abstract] [Full Text] [Related]
56. [Successful treatment of severe HCV-cryoglobulinemic vasculitis with the use of CD20 monoclonalantibodies and antiviral agents].
Ignatova TM; Chernova OA; Burnevich EZ; Milovanova SIu
Klin Med (Mosk); 2014; 92(8):62-4. PubMed ID: 25790700
[TBL] [Abstract][Full Text] [Related]
57. Acute wrist and foot drop associated with hepatitis C virus related mixed cryoglobulinemia: rapid response to treatment with rituximab.
Uppal R; Charles E; Lake-Bakaar G
J Clin Virol; 2010 Jan; 47(1):69-71. PubMed ID: 19892591
[TBL] [Abstract][Full Text] [Related]
58. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
[TBL] [Abstract][Full Text] [Related]
59. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature.
Pouchelon C; Visentini M; Emmi G; le Guern V; Quartuccio L; Samson M; Venhoff N; Briantais A; Casato M; Chatelus E; Chilles M; Cid MC; Diot E; Ebbo M; Faguer S; Hellmich B; Jachiet M; Moulinet T; Perrin F; Quémeneur T; Sinico RA; Terrier B
Autoimmun Rev; 2022 Apr; 21(4):103034. PubMed ID: 34995764
[TBL] [Abstract][Full Text] [Related]
60. [Kidney involvement in mixed cryoglobulinemia: which treatment?].
Cacoub P
Presse Med; 2012 Mar; 41(3 Pt 1):254-9. PubMed ID: 22192935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
